These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 10948319)
1. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Kurosumi M; Tabei T; Suemasu K; Inoue K; Kusawake T; Sugamata N; Higashi Y Oncol Rep; 2000; 7(5):945-8. PubMed ID: 10948319 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Layman RM; Thomas DG; Griffith KA; Smerage JB; Helvie MA; Roubidoux MA; Diehl KM; Newman LA; Sabel MS; Hayman JA; Pierce LJ; Hayes DF; Schott AF Clin Cancer Res; 2007 Jul; 13(14):4092-7. PubMed ID: 17634534 [TBL] [Abstract][Full Text] [Related]
3. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Goble S; Bear HD Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604 [TBL] [Abstract][Full Text] [Related]
4. [Intra-arterial infusion chemotherapy with docetaxel for locally advanced breast cancer and inflammatory breast cancer]. Doi K; Ohchi T; Kudo S; Takahashi M; Sakamoto T; Ochiai T; Sakae T; Ishihara A Gan To Kagaku Ryoho; 2000 Oct; 27(12):1823-5. PubMed ID: 11086421 [TBL] [Abstract][Full Text] [Related]
5. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Sparano JA Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388 [TBL] [Abstract][Full Text] [Related]
6. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. Fujimoto-Ouchi K; Tanaka Y; Tominaga T Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360 [TBL] [Abstract][Full Text] [Related]
7. Comparison of ELISA level and immunohistochemical status for thymidine phosphorylase (TP) in invasive breast carcinoma. Kurosumi M; Sugamata N; Tabei T; Inoue K; Matsumoto H; Suemasu K; Higashi Y Anticancer Res; 2002; 22(1A):331-8. PubMed ID: 12017313 [TBL] [Abstract][Full Text] [Related]
8. [Docetaxel was effective as neoadjuvant chemotherapy for patients after failure of trans-arterial neoadjuvant chemotherapy with CEF in 2 cases of advanced breast cancer]. Ogawa T; Nagata S; Suzuki H; Onzuka T; Yamanaka N; Kawano R; Yoshida J; Shinohara M; Sumitomo K; Matsuo K; Kuroki S Gan To Kagaku Ryoho; 2001 Oct; 28(11):1743-5. PubMed ID: 11708023 [TBL] [Abstract][Full Text] [Related]
9. [A case report: effective trans-arterial neoadjuvant chemotherapy with docetaxel for a local advanced breast cancer patient]. Sakita I; Tamaki Y; Miyazaki M; Kadota M; Masuda N; Ooka M; Ohue M; Sekimoto M; Tomita N; Monden M Gan To Kagaku Ryoho; 1999 Oct; 26(12):1955-8. PubMed ID: 10560435 [TBL] [Abstract][Full Text] [Related]
10. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Toi M; Bando H; Horiguchi S; Takada M; Kataoka A; Ueno T; Saji S; Muta M; Funata N; Ohno S Br J Cancer; 2004 Jun; 90(12):2338-43. PubMed ID: 15150550 [TBL] [Abstract][Full Text] [Related]
11. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Gradishar WJ Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):15-8. PubMed ID: 9364536 [TBL] [Abstract][Full Text] [Related]
12. Docetaxel: an update of its use in advanced breast cancer. Figgitt DP; Wiseman LR Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837 [TBL] [Abstract][Full Text] [Related]
13. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. Han JY; Hong EK; Lee SY; Yoon SM; Lee DH; Lee JS J Clin Pathol; 2005 Jun; 58(6):650-4. PubMed ID: 15917420 [TBL] [Abstract][Full Text] [Related]
14. The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer. Gogas H; Fountzilas G Ann Oncol; 2003 May; 14(5):667-74. PubMed ID: 12702519 [No Abstract] [Full Text] [Related]
15. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy]. Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786 [TBL] [Abstract][Full Text] [Related]
16. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456 [TBL] [Abstract][Full Text] [Related]
17. [A trial for neoadjuvant chemotherapy of transarterial infusion of docetaxel in locally advanced breast cancer]. Ohchi T; Kudo S; Doi K; Takahashi M; Sakamoto T; Ochiai T; Sakae T; Ishihara A; Kimura Y; Inoue K Gan To Kagaku Ryoho; 2000 Jan; 27(1):143-5. PubMed ID: 10660749 [No Abstract] [Full Text] [Related]
18. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Tsavaris N; Kosmas C; Vadiaka M; Kanelopoulos P; Boulamatsis D Br J Cancer; 2002 Jul; 87(1):21-7. PubMed ID: 12085250 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. Smith IC; Heys SD; Hutcheon AW; Miller ID; Payne S; Gilbert FJ; Ah-See AK; Eremin O; Walker LG; Sarkar TK; Eggleton SP; Ogston KN J Clin Oncol; 2002 Mar; 20(6):1456-66. PubMed ID: 11896092 [TBL] [Abstract][Full Text] [Related]
20. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Estévez LG; Cuevas JM; Antón A; Florián J; López-Vega JM; Velasco A; Lobo F; Herrero A; Fortes J Clin Cancer Res; 2003 Feb; 9(2):686-92. PubMed ID: 12576436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]